|
Jul 2
|
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
|
|
Jun 10
|
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
|
|
May 23
|
Inventiva reports 2025 First Quarter Financial Information¹
|
|
May 23
|
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
|
|
May 22
|
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux
|
|
Apr 30
|
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
|
|
Apr 30
|
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
|
|
Apr 24
|
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
|
|
Feb 26
|
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
|
|
Feb 10
|
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
|